SEATTLE--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Denis Sirringhaus has joined the company as Vice President of Business Development.
“We are thrilled to welcome Denis to our team,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “Denis’ expertise is perfectly aligned to drive the partnerships essential for AltPep to achieve its mission of transforming the treatment and detection of amyloid diseases, such as Alzheimer’s.”
Denis most recently served as Executive Director of Business Development at Caribou Biosciences where he helped secure a $25M Pfizer investment that led to a $100M+ follow-on offering. Prior to Caribou, Denis worked in Business Development at several biopharma companies, including Gossamer Bio and Genentech/Roche where he evaluated neuroscience assets including the in-license of Enspryng® and the acquisition of Spark Therapeutics. He started his career at JPMorgan on the Specialty Pharma equity research team. Denis holds an MBA from Wharton, a Master’s in Biotechnology from the University of Pennsylvania, and an AB in Biological Sciences from Harvard.
Denis Sirringhaus expressed his enthusiasm about joining AltPep stating, “I am excited to be part of the team and look forward to identifying the best partners for AltPep’s late pre-clinical program in Alzheimer’s, the SOBA diagnostic based on the same technology, and other pipeline candidates based on AltPep’s unique alpha-sheet targeting peptide platform.”
About AltPep Corporation
AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep’s emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep’s goal is to change the course of these debilitating diseases that affect over a billion people around the globe.
Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep’s innovative approach.
For more information, please visit altpep.com and follow us on LinkedIn.
